AMO Pharma Shows Weakness In Myotonic Dystrophy

 
• By Elizabeth Cairns

A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.

A man shows a thumb down. Gesture of disapproval and rejection. Bad assessment, harsh criticism, failure and defeat. Refusal to pass and cooperation. Bureaucratic obstacles. Contempt and condemnation

More from Clinical Trials

More from R&D